Search »
- Use quotation marks (e.g., "RSR Manual") to search for exact phrases.
- You must be logged in to search for people in the Ryan White/TargetHIV community.
Content type
Topic Areas
Source
Publication Date
-
News Article updated on 10/01/2021
-
HAB Releases New Policy Notice Simplifying Core Medical Services Waiver Requirements
From HRSA's HIV/AIDS Bureau - 10/1/2021 - Dear Ryan White HIV/AIDS Program Colleagues:
News Article updated on 10/04/2021 -
Four Things to Know About Open Enrollment 2022
-
Ryan White Part A-F Awards Announced for FY21
From the HRSA HIV/AIDS Bureau Update: Special Bulletin - 10/5/21
News Article updated on 10/06/2021 -
Use of CARES Act Funds and Vaccine Incentives
A new FAQ has been added to the HRSA HIV/AIDS Bureau's Coronavirus Disease 2019 (COVID-19) Frequently Asked Questi
News Article updated on 08/31/2021 -
Hybrid Format for Ryan White 2022
Next year’s Ryan White Conference will adopt an in-person/virtual format, while the Clinica
News Article updated on 10/15/2021 -
Rapid ART: An Essential Strategy for Ending the HIV Epidemic
What HIV care providers can do to create a rapid ART program to get HIV clients on treatment the same day as a diagnosis.Resource updated 09/19/2023
-
Four things to know about Open Enrollment 2022
To help you stay on top of the latest updates, the ACE TA Center has compiled this list of four “things to know” about helping consumers navigate this year’s Marketplace Open Enrollment.Blog updated 11/09/2021
-
Rapid ART Playbook Outlines Steps to Implementation
Guide on implementing rapid ART the administration of antiretroviral therapy (ART) as quickly as possible and ideally on the same day as an HIV diagnosis/clinic visit.Blog updated 03/03/2022
-
TAP-in EHE Webinar Series
Recordings of the TAP-in webinars on topics critical to the Ending the HIV Epidemic Initiative.Resource updated 05/23/2023
-
HRSA Revises RWHAP Policy Notice on Eligibility Determinations
In October 2021, HRSA's HIV/AIDS Bureau revised its client eligibility and recertification policy for the Ryan White HIV/AIDS Program.
News Article updated on 11/02/2021 -
RWHAP CARES Act Expenditures Report
How to access the RWHAP CARES Act Expenditures Report and instructions on CARES Act Expenditures Reporting.Resource updated 12/22/2023
-
Use of Social Media and Mobile Technology as Essential Tools for EHE
Strategies to engage hard-to-reach youth and young adults through use of social media and related technologies.Resource updated 03/15/2023
-
Marketplace Subsidies and Unemployment Compensation
New Marketplace subsidies are available for people who received unemployment compensation in 2021.Blog updated 12/15/2021
-
Reviewing the RWHAP Program Terms Report/Allocations Report for Project Officers
How to access the Program Terms Report (PTR)/Allocations Report and steps a Project Officer should take in reviewing PTRs and the submission timeline.Resource updated 04/11/2023
-
Ending the HIV Epidemic through Innovations in Rapid ART
Review of innovative Rapid ART strategies in diverse settings.Resource updated 03/15/2023
-
Medical Monitoring Project 2019-2020 Data on HIV Care Access and Health Outcomes
In the U.S., almost all people with HIV have some type of health insurance coverage (pub
News Article updated on 08/09/2021 -
Innovation and Resilience: How Ryan White HIV/AIDS Program Recipients Leverage Telehealth during the COVID-19 Pandemic
Recap of changes made in telehealth laws, regulations, and policies and corresponding efforts of healthcare systems, payers, and providers to modify their services to keep clients with HIV engaged in care provided by HRSA's Ryan White HIV/AIDS Program.Resource updated 06/09/2022
-
New Investigational ART Drugs and Strategies
Review of investigational drugs in phase III trials (as of 2021: Islatravir, Lenacapravir, GSK 3640254/aka GSK “254) and how these investigational agents might be used in treatment in the future. Also, review of long-acting injectables.Resource (Conference Presentation) updated 09/14/2023
-
Managing Polypharmacy and Drug-Drug Interactions
Review of common mechanisms for drug interactions with contemporary ART; therapeutic classes of drugs with high interaction potential with ART; distinctions between oral vs intramuscular cabotegravir/rilpivirin interactions; and comparison of the clinical pharmacology and drug interaction potential of tenofovir alafenamide vs tenofovir disoproxilfumarate.Resource (Conference Presentation) updated 09/14/2023